Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DCTH vs AXGN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AXGN Captures Overall Composite Edge (33.1 SELL vs 35.9 SELL), While DCTH Leads 4–2 on Growth & Valuation Pillars
AXGN Overall Winner
6-Pillar Tally: DCTH 4 – 2 AXGN
Matrix Metrics: DCTH 5 – 5 AXGN
As of Nov 16, 2026, Axogen, Inc. (AXGN) captures the overall head-to-head institutional edge over Delcath Systems Inc (DCTH) on higher Unified Composite conviction (33.1/100 SELL vs. 35.9/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while DCTH wins 4–2 across the 6-pillar growth and valuation breakdown. DCTH trades at $19.68 (N/M Forward P/E, 5.2% operating margin) versus AXGN at $55.35 (79.3x Forward P/E, -5.2% operating margin).
- Composite vs. Pillar Nuance: While DCTH currently prints a higher short-term Unified Composite Score (35.9/100 SELL vs. AXGN 33.1/100 SELL), AXGN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 5.2% operating margin) and revenue trajectory (+26.2% vs. +70.7% YoY).
- Defensive Composite Rating Caution: Although AXGN compares more favorably head-to-head, both DCTH (35.9/100 SELL) and AXGN (33.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DCTH vs AXGN
DCTH
Delcath Systems Inc
$19.68
-4.23% 1D
Market Cap
$743.8M
TTM Revenue
$110M
Forward P/E
N/M
Beta / 30D Vol
1.63β · 131% Vol
Unified Composite Score
35.9
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
AXGN
Head-to-Head Winner
Axogen, Inc. Common Stock
$55.35
-1.03% 1D
Market Cap
$3.3B
TTM Revenue
$267M
Forward P/E
79.3x
Beta / 30D Vol
1.28β · 123% Vol
Unified Composite Score
33.1
SELL
Tech 50.0
Fund 34.0
Flow 62.0
Mom 50.0
Weinstein Technical Phase
Neutral · Hold
6-Pillar Scorecard Institutional Category Breakdown (DCTH 4 – 2 AXGN)
1. Valuation Multiples
AXGN
Forward P/E
N/M
79.3x
Trailing P/E
133.6x
128.2x
PEG Ratio
1.60x
N/M
EV / Revenue
6.3x
11.2x
2. Growth & Scale
DCTH
Revenue Growth (YoY)
+70.7%
+26.2%
Earnings Growth (YoY)
+750.0%
+300.0%
TTM Revenue (USD)
$110M
$267M
Market Cap
$743.8M
$3.3B
3. Profitability & Quality
DCTH
Gross Margin
87.6%
74.2%
Operating Margin
5.2%
-5.2%
Net Profit Margin
6.0%
-12.0%
Return on Equity (ROE)
5.4%
-10.3%
4. Balance Sheet & Cash Flow
DCTH
Cash Generation (TTM)
$20M
$20M
Cash Flow Margin
18.3%
7.5%
Net Cash / Leverage
$53M Net Cash
$309M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
AXGN
Options Structure Phase
BREAKOUT
BREAKOUT
Current IV / %ile
109.3% (43rd %ile)
58.6% (12th %ile)
Put/Call OI Skew
0.11x (Call-Skewed)
0.01x (Call-Skewed)
OBV Trend / Tech Phase
ACCUMULATION · Neutral
ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat
DCTH
OpEx & R&D Intensity
82.4% of Rev ($91M)
79.4% of Rev ($212M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Medical Devices Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DCTH (5) vs AXGN (5)| Institutional Metric | DCTH | AXGN | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $743.8M | $3.3B | AXGN | |
| Trailing P/E Ratio | 133.6x | 128.2x | AXGN | |
| Forward P/E Ratio | N/M | 79.3x | AXGN | |
| Revenue Growth (YoY) | +70.7% | +26.2% | DCTH | |
| Operating Margin (TTM) | 5.2% | -5.2% | DCTH | |
| Net Profit Margin | 6.0% | -12.0% | DCTH | |
| Return on Equity (ROE) | 5.4% | -10.3% | DCTH | |
| 52-Week Range Position | 80% ($8–$23) | 88% ($23–$60) | AXGN | |
| Beta / 30D Volatility | 1.63β · 131% Vol | 1.28β · 123% Vol | AXGN | |
| Unified Institutional Score | 35.9 / 100 (SELL) | 33.1 / 100 (SELL) | DCTH | |
| Trailing 12M Revenue (USD) | $110M | $267M | Scale | |
| Gross Profit Margin (TTM) | 87.6% | 74.2% | Quality | |
| PEG Ratio & EV / Revenue | 1.60x PEG · 6.3x EV/Rev | N/M PEG · 11.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $20M ($53M Net Cash) | $20M ($309M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
AXGN +20.12 pp
3M Horizon
DCTH +6.44 pp
6M Horizon
DCTH +45.51 pp
1Y Horizon
AXGN +1.69 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DCTH Revenue | AXGN Revenue | DCTH Op. Margin | AXGN Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | N/A | $80M | N/A | -24.4% | AXGN |
| FY2019 | N/A | $110M | N/A | -29.4% | AXGN |
| FY2020 | N/A | $110M | N/A | -20.6% | AXGN |
| FY2021 | $0M | $130M | -690.0% | -20.0% | AXGN |
| FY2022 | $0M | $140M | -1245.1% | -21.4% | AXGN |
| FY2023 | $0M | $160M | -1849.0% | -13.5% | AXGN |
| FY2024 | $40M | $190M | -33.4% | -1.8% | AXGN |
| FY2025 | $90M | $230M | 0.8% | -3.5% | DCTH |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DCTH
BREAKOUT
Current IV
109.3%
IV Percentile
43rd %ile
Put/Call OI Skew
0.11x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact DCTH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
AXGN
BREAKOUT
Current IV
58.6%
IV Percentile
12th %ile
Put/Call OI Skew
0.01x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact AXGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DCTH Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
82.4% of Rev ($91M)
90D Engineering Disclosures
0 Published
AXGN Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
79.4% of Rev ($212M)
90D Engineering Disclosures
0 Published
Investor FAQ DCTH vs AXGN Key Questions & Quantitative Answers
As of Nov 16, 2026, Axogen, Inc. (AXGN) captures the overall head-to-head institutional edge over Delcath Systems Inc (DCTH) on higher Unified Composite conviction (33.1/100 SELL vs. 35.9/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Options & Positioning), while DCTH wins 4–2 across the 6-pillar growth and valuation breakdown. DCTH trades at $19.68 (N/M Forward P/E, 5.2% operating margin) versus AXGN at $55.35 (79.3x Forward P/E, -5.2% operating margin). Composite vs. Pillar Nuance: While DCTH currently prints a higher short-term Unified Composite Score (35.9/100 SELL vs. AXGN 33.1/100 SELL), AXGN captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 5.2% operating margin) and revenue trajectory (+26.2% vs. +70.7% YoY). Defensive Composite Rating Caution: Although AXGN compares more favorably head-to-head, both DCTH (35.9/100 SELL) and AXGN (33.1/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
DCTH leads the Growth & Scale pillar: DCTH posts +70.7% YoY revenue growth and +750.0% YoY earnings growth on $110M TTM revenue (87.6% gross margin, 5.2% operating margin), compared with AXGN at +26.2% YoY revenue growth and +300.0% YoY earnings growth on $267M TTM revenue (74.2% gross margin, -5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DCTH cumulative revenue shifted +125.0% while AXGN shifted +187.5%. In operating R&D and SG&A reinvestment, DCTH deploys 82.4% of Rev ($91M) (0 90-day corporate R&D disclosures) versus 79.4% of Rev ($212M) (0 disclosures) for AXGN.
AXGN screens cheaper on headline valuation multiples. DCTH trades at N/M Forward P/E, 133.6x Trailing P/E, 1.60x PEG, and 6.3x EV/Revenue (18.3% FCF margin), whereas AXGN trades at 79.3x Forward P/E, 128.2x Trailing P/E, N/M PEG, and 11.2x EV/Revenue (7.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DCTH (5.4% ROE) versus AXGN (-10.3% ROE) capital efficiency.
In options market volatility and institutional positioning, DCTH carries 109.3% implied volatility (43rd %ile, Balanced (25th–60th %ile)), a 0.11x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.63β · 131% Vol realized risk). By comparison, AXGN carries 58.6% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.28β · 123% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
AXGN vs DCTH · Reverse Pair
DCTH vs CRMD
· Sector Peer
AXGN vs ATRC
· Sector Peer
AXGN vs ANAB
· Sector Peer
AXGN vs LIVN
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma